Unicocell Biomed Co Ltd
Unicocell Biomed Co Ltd is a biotechnology and medical research company that operates in the pharmaceuticals and medical research sector, primarily generating revenue through the development and commercialization of biomed-related products and services.
Business. Unicocell Biomed Co Ltd (6794.TW) is a biotechnology and medical research company operating within the healthcare sector. The firm is primarily engaged in pharmaceuticals and medical research activities. It is listed on the Taiwan Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Unicocell Biomed Co Ltd (6794.TW) is a biotechnology and medical research company operating within the healthcare sector. The firm is primarily engaged in pharmaceuticals and medical research activities. It is listed on the Taiwan Stock Exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Unicocell Biomed Co Ltd maintains a strong liquidity position with a current ratio of 37.98, indicating that its current assets significantly exceed its current liabilities. However, the company has a negative net cash position after subtracting total debt, which raises liquidity concerns. The company's debt-to-equity ratio is 0.07, suggesting a relatively low reliance on debt financing compared to equity.
The company's profitability is currently negative, with a return on equity of -13.27% and a return on assets of -12.14%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The operating loss of TWD 130,278,000 and net loss of TWD 114,836,000 further underscore the company's financial challenges.
Unicocell Biomed Co Ltd's revenue is concentrated in a single segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher risks if its primary market or product line experiences a downturn.
The company's growth trajectory is currently negative, with a significant operating and net loss. The operating cash flow of TWD -91,310,000 and free cash flow of TWD -100,013,000 indicate that the company is not generating sufficient cash from operations to sustain its activities or fund growth initiatives. The capital expenditure of TWD -5,727,000 suggests minimal investment in long-term assets, which may limit future growth potential.
The company faces medium liquidity risk due to its negative net cash position after subtracting total debt. While the dilution risk is currently low, the company's financial performance and cash flow challenges may necessitate future equity or debt financing, which could lead to dilution. The risk assessment highlights the need for the company to improve its cash flow generation and reduce its operating losses to maintain financial stability.
Recent financial filings and transcripts indicate that the company is actively managing its financial position, but the negative operating and net income suggest ongoing challenges in achieving profitability. The company's management has not disclosed specific strategies to address these issues in the available documents.
- Unicocell Biomed Co Ltd has a strong liquidity position as indicated by its high current ratio, but its negative net cash position after subtracting total debt raises concerns.
- The company is currently unprofitable, with significant operating and net losses, and negative returns on equity and assets.
- Revenue is concentrated in a single segment, and there is no geographic diversification provided in the available data.
- The company's growth trajectory is negative, with substantial operating and free cash flow deficits.
- The company faces medium liquidity risk and low dilution risk, but its financial performance may necessitate future financing that could lead to dilution.
- "margin_outlook_rationale": "The company's margin outlook is negative due to its significant operating and net losses, which indicate declining profitability.",
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Unicocell Biomed Co Ltd Market data — financials · 2026-05-27